Results 291 to 300 of about 218,509 (395)

The exposomal imprint on rosacea: More than skin deep

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Rosacea reflects systemic and environmental interactions, not just a skin disorder. Key factors include environmental triggers, genetic and microbiome influences, diagnostic gaps in skin of colour and social determinants. Advances in multi‐omics and exposome integration highlight pathways towards precision medicine, prevention and equitable, patient ...
Katerina Grafanaki   +3 more
wiley   +1 more source

Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Forty‐three HS specialists from 22 European countries reported adherence to HS guidelines and use of antibiotics before biologics despite limited efficacy and rapid relapse (49% within 1–3 months). Seventy‐nine per cent supported short‐term biologics for severe Hurley I disease.
Georgios Nikolakis   +41 more
wiley   +1 more source

Hair follicle stem cell fate supports distinct clinical endotypes in hidradenitis suppurativa

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Hair follicles (HFs) were extracted from skin biopsies. From these, original sequencing data were obtained and integrated with two independent studies to build a HF single‐cell transcriptomic atlas. It enabled delineating the fate of HF stem cells.
Audrey Onfroy   +17 more
wiley   +1 more source

An Updated Review of Topical Tretinoin in Dermatology: From Acne and Photoaging to Skin Cancer. [PDF]

open access: yesJ Clin Med
Balado-Simó P   +6 more
europepmc   +1 more source

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy